Laureate’s clients obtain access to Boehringer’s manufacturing platform.

Laureate Pharma’s clients will gain access to Boehringer Ingelheim’s manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture.

Under this preferred partnership agreement, Laureate says the firm will now offer its clients bioprocessing services that include creation and development of production cell lines using Boehringer Ingelheim’s BI HEX expression system, full-service process development and manufacture of early-stage clinical supplies at Laureate’s cGMP manufacturing facility in Princeton, NJ, and access to large-scale commercial production by Boehringer Ingelheim at its facility in Biberach, Germany.

The companies will work together to ensure smooth transfer of manufacturing activities from Laureate to Boehringer Ingelheim, notes Robert J. Broeze, Ph.D., president and CEO of Laureate Pharma.

This collaboration complements Laureate’s current service offerings with cell line development along with large-scale manufacturing capabilities, adds Dr. Broeze.

Previous articleAstraZeneca to Pay up to $120M for Regeneron’s Mab Discovery Platform
Next articleAntisense and Isis Extend Pact